NMCC aggressively manages cancer and the side effects of the disease and treatment to help patients feel better and spend more time at home. This method of treatment is called a "medical home," and we're so successful at it that our CEO Dr. Barbara McAneny received a grant to duplicate the process at six clinics across the country. As part of the grant, we offer treatment until 8 p.m. during the week and from 1 to 4 p.m. on weekends so our patients don't seek care in the ER.
Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer
The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) d... Continue Reading
FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer
The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted for the tr... Continue Reading
NMCC’s CEO Dr. Barbara McAneny spoke recently about pancreatic cancer and how it’s treated. Listen to the interview here.
NMCC’s Dr. Jose Avitia spoke with KKOB’s Terrie Q. Sayre about healthcare and cancer care. Listen to the interview here.
New Mexico Cancer Center (NMCC) is one of six award winners for the 2014 Association of Community Cancer Centers’ (ACCC) Innovator Awards. Established in 2011, ACCC’s Innovator Awards honor exceptional cancer programs that demonstrate forward-thinking strategic planning and have delivered pioneering, replicable programs for cancer care delivery. As an award recipient, NMCC presented the details and outcomes of their ongoing work at the ACCC National Oncology Conference before more than 500 cancer care providers from across the country in San Diego last month. Read about the event here.